Merck to pay $425 million upfront to buy COVID-19 treatment developer OncoImmuneMarket Watch • 11/23/20
Merck Submits Applications for Licensure of V114, the Company's Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults to the U.S. FDA and European Medicines AgencyBusiness Wire • 11/23/20
Jeff Reeves's Strength in Numbers: These 5 stocks will profit from the dollar's continuing declineMarket Watch • 11/22/20
Warren Buffett's Berkshire Hathaway plowed more than $5 billion into 4 pharma stocks last quarter. He's been teasing a bet on the sector for more than 20 yearsBusiness Insider • 11/18/20